Amgen readies for GLP‑1 boom, faces Lilly rivalry and access/manufacturing challenges

Amgen positions for a GLP‑1 surge as obesity care shifts

Amgen is preparing to compete in a rapidly changing obesity-treatment market as GLP‑1 and related modalities reshape care away from traditional diet-and-exercise approaches. Market leaders such as Eli Lilly are defining efficacy and safety benchmarks with tirzepatide, and Barclays highlights a pipeline wave of entrants — including Amgen — that will follow as the market segments into oral agents, higher-efficacy injectables and combination regimens. For Amgen, the immediate task is translating its biologics and peptide expertise into products and programmes that can credibly challenge established agents on both efficacy and tolerability.

Amgen’s strategic choices centre on clinical differentiation and commercial access. The company must weigh whether to prioritise next‑generation injectables that target superior efficacy with tolerable toxicity profiles, or to develop once‑daily oral alternatives that lower barriers to use. Success depends on demonstrating clear clinical value in head‑to‑head or comparative studies, securing favourable reimbursement pathways as Medicare and private payers revise coverage, and adapting sales and patient‑support models to meet consumer demand that is increasingly driven by direct‑to‑consumer channels and real‑world convenience.

Operationally, Amgen faces a multi‑front challenge: accelerate late‑stage development, plan for scalable manufacturing of peptide and biologic therapies, and build patient access systems that can handle rapid volume growth if launches succeed. The company’s existing biologics commercial infrastructure and large sales footprint provide advantages, but they also require retooling for chronic obesity management — an indication with different adherence, monitoring and pharmacy distribution dynamics compared with many specialty biologics.

Lilly’s lead reshapes the competitive playbook

Barclays’ recent initiation of coverage on Eli Lilly stresses tirzepatide’s current leadership and the defensive power of Lilly’s patient‑centric Lilly Direct platform, which is increasing consumer access and may blunt newcomers’ share gains as Medicare coverage expands and price dynamics evolve. The Barclays note also flags orforglipron — a once‑daily oral GLP‑1 expected around mid‑2026 — as a key market catalyst that will alter the competitive calculus.

Analyst coverage of Amgen reflects market uncertainty

Eighteen analyst ratings on Amgen in the past three months signal heightened engagement and divergent views on the company’s prospects in this new therapeutic era. The mix of bullish and cautious takes underscores the importance of tracking Amgen’s trial readouts, regulatory filings and access strategies to assess how the company stakes its claim in the GLP‑1 and obesity treatment landscape.